A Phase Ib Study Evaluating the Safety and Efficacy of IBI188 in Combination With Azacitidine in Subjects With Newly Diagnosed Higher Risk Myelodysplastic Syndrome
Latest Information Update: 20 Feb 2023
At a glance
- Drugs Azacitidine (Primary) ; Letaplimab (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Innovent Biologics
- 14 Feb 2023 Planned number of patients changed from 12 to 120.
- 14 Feb 2023 Planned End Date changed from 20 Feb 2022 to 20 Aug 2024.
- 14 Feb 2023 Planned primary completion date changed from 5 Dec 2021 to 30 Dec 2023.